Psilocybin-Research.com Research. Clarity. Progress.
Loading
Psilocybin-Research.com Research. Clarity. Progress.

Your gateway to psilocybin research

Psilocybin and psilocin literature, kept searchable and usable.

Search settings and shortcuts
Database up to date Updated Jul 3, 2026 01:22 UTC
Database 3,975 indexed records
3,975 Total Publications 3,834 Psilocybin Records 553 Psilocin Records 3,975 Search Matches 388 Journals 66 Research Topics
Published 3,210 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,554 64.3% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 283 7.1% Active
PsyArXiv 216 5.4% Active
Crossref 157 3.9% Active
bioRxiv 142 3.6% Active
Publication timeline 3,072 dated records
3,072 records since 2020
Annual records Cumulative line
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Default publication index

Latest publications

3,975 records from the full SQLite publication database, sorted by newest first.

Result settings and exports
Updated Jul 3, 2026 01:22 UTC
Checking for newly published papers...
Page 25 of 199

Acute psilocin increased cortical activity in rat.

Psilocin, a naturally occurring hallucinogenic component of magic mushrooms, exerts notable psychoactive effects in both humans and rodents. However, the underlying mechanisms remain not fully understood. Blood-oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) is a valuable tool in many preclinical and clinical trials for invest...

Unknown journal 2026-02-03 Liu J, Wang Y, Xia K, Wu J, Zheng D, Cai A, Yan H, Su R.
Europe PMC Published psilocybinpsilocin DepressionBrain ImagingMechanism of ActionAgingClinical TrialAnimal Study Clinical Trial

Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia

Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder, and anorexia nervosa (AN). These disorders often share social deficits that may be effectively alleviated by psychedelics considering their use has been linked with emotional empathy and ...

Psychedelics 2026-02-02 Shadani Sheida, Greaves Erika, Andrews Zane B., Foldi Claire J.
Crossref Published psilocybin DepressionAnxietyOCDEating DisordersMechanism of ActionEmotional ProcessingAnimal StudyInflammationImmune Function Animal Study

Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study

Introduction: Cognitive flexibility is essential for behavioral adaptation in response to environmental changes and is impaired in various neuropsychiatric disorders. The serotonergic psychedelic psilocybin has shown potential in enhancing cognitive flexibility, although with mixed results. In this study, we investigated the effects of psilocybin on cognitiv...

Psychedelic Medicine 2026-02-02 Gregersen Anton T., Whelan Tobias, Golden Caroline, Blackmore Thomas, Palner Mikael
Crossref Published psilocybin Drug Interactions Other

MDMA and Psilocybin Regulate Oligodendrocyte-Lineage Cell Numbers and Anxiety-Like Behaviors in a Rat Model of Fear.

BackgroundPsilocybin and MDMA produce rapid, enduring therapeutic effects in posttraumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. In this study, we investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioni...

Unknown journal 2026-02-02 Bostancıklıoğlu M, Kaplan DS, Bal R, Yiğit E, Ulusal H, Temiz E.
Europe PMC Published psilocybin AnxietyPTSDNeuroplasticityMechanism of ActionReceptor PharmacologyBiomarkersAnimal StudyTranscriptomicsProteomicsMetabolomics Animal Study

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.

As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite ...

Unknown journal 2026-02-02 Mallaroni P, Singleton SP, Mason NL, Satterthwaite TD, Ramaekers JG.
Europe PMC Published psilocybin Brain ImagingPharmacologyReceptor PharmacologyBiomarkersAgingHealthy Volunteers Other BrainHumans

Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models

Abstract Large language models (LLMs) are increasingly consulted by individuals for support during psychedelic experiences ("trip sitting"), yet no framework exists to evaluate whether these models can accurately simulate or safely respond to altered states of consciousness. We aimed to determine if LLMs can be induced to generate narratives resembling human...

Research Square 2026-02-01 Ben-Zion Z, Simon G, Lazebnik T.
Europe PMC PREPRINT (not peer reviewed) psilocybin ConsciousnessMystical ExperienceSafety Other

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

BackgroundClassic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited.MethodsThis study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psyc...

Unknown journal 2026-02-01 Aboulafia-Brakha T, Buchard A, Mabilais C, Alaux S, Amberger C, Furtado L, Seragnoli F, Briefer JF, Thorens G, Sabé M, Szczesniak L, Iuga R, Zullino D, Penzenstadler L.
Europe PMC Published psilocybin DepressionAnxietyEmotional ProcessingObservational StudySafetyAdverse Events Observational Study HumansLysergic Acid Diethylamide

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.

There has been a renewed interest in the use of various psychedelic agents as potential therapies for multiple psychiatric conditions, including post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), to name a few. This follows the recent accumulation of evidence for ketamine pharmacotherapy and a rapid pr...

Canadian journal of psychiatry. Revue canadienne de psychiatrie 2026-01-31 Swainson J, Brietzke E, Khullar A, McIntyre RS, Soares CN
PubMed Published psilocybin DepressionAnxietyPTSDMechanism of ActionClinical Trial Clinical Trial MDMAPTSD

Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.

The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress dis...

Neurologic clinics 2026-01-31 Ansari M, Elliott SI, Holmes SE, Sanacora G
PubMed Published psilocybin DepressionPTSDMechanism of ActionReview Article Review Article AntidepressantKetamine

Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.

Naturalistic psychedelic use can result in a range of difficulties that impair social, occupational, and other important areas of functioning. Yet, the prevalence, phenomenology, and etiology of these outcomes remain poorly understood. Recent qualitative research has shown that individuals with long-term difficulties after psychedelic use sometimes attribute...

The International journal on drug policy 2026-01-31 Olofsson M, Osika W, Goldberg SB, Hendricks PS, Petrovic P, White T, Stenfors CUD, Chaturvedi S, Simonsson O
PubMed Published psilocybin AnxietySafety Qualitative Study AdverseChallenging experiences

Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy.

IntroductionAlthough commonly used in psychedelic-assisted therapy, the role of therapeutic touch remains loosely defined and ethically sensitive. Gaining insight into how participants experience and interpret touch during psychedelic sessions is essential for informing safe and effective clinical practice.MethodsParticipants were sampled from a large random...

Unknown journal 2026-01-31 Ham R, Gardner J, Carter A, Liknaitzky P.
Europe PMC Published psilocybin Emotional ProcessingClinical TrialSafety Clinical Trial HumansHallucinogens

Psychedelic- and Substance-Assisted Therapies in Global Mental Health: Bridging Cultures, Evidence, and Access.

Psychedelic- and substance-assisted therapies, including MDMA, psilocybin, and ketamine, are gaining attention for conditions such as PTSD and depression, yet their development and implementation remain largely concentrated in high-income settings. This graphical abstract summarizes the central argument of the commentary: while these interventions may hold r...

Unknown journal 2026-01-31 Halm S.
Europe PMC Published psilocybin DepressionPTSDMechanism of Action Other HumansN-Methyl-3

We Licked the Toads so You Don't Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5-Methoxy-N,N-Dimethyltryptamine.

Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are found in many plants but also excreted by some species of toads. The compounds are regulated differently around the world, and although used in traditional medicine, 20-century prohibition culture has slowed resea...

ChemMedChem 2026-01-31 Homon A, Laramie J, Hayward JJ, Trant JF
PubMed Published psilocin Receptor PharmacologyReview ArticleAnimal StudyInflammation Review Article 5-HT receptorspsilocin derivatives

[Pharmacological post-acute treatment of alcohol use disorder: Established strategies and innovative approaches].

IntroductionAlcohol use disorders are common and contribute significantly to the global burden of disease. The treatment of alcohol dependence includes the acute withdrawal phase and the post-acute rehabilitation phase. The primary goal of post-acute treatment is long-term abstinence, although reduction of alcohol consumption is also recognized as an interme...

Unknown journal 2026-01-31 Roser P.
Europe PMC Published psilocybin AddictionReceptor PharmacologySafety Clinical Trial HumansAlcoholism

Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice.

The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the f...

Unknown journal 2026-01-31 Kala K, Bederska-Lojewska D, Lazur J, Gasior K, Maslanka A, Szewczyk A, Sulkowska-Ziaja K, Turek J, Szewczyk B, Pilc A, Muszynska B.
Europe PMC Published psilocybin DepressionAnxietyMicrodosingAnimal StudyIn Vitro Study Animal Study AnimalsMice

Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects

Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biological mechanisms supporting durability beyond the acute drug effect. [5,7] Mechanistic accounts increasingly focus on neuroplasticity as a candidate pathway linking transient serotonergic receptor activation to lo...

Quality in Sport 2026-01-30 Komarczewska Anna Maria, Matusiak Filip, Brzoza Klaudia, Kociński Michał, Iglewski Patryk, Pietrasz Michał
Crossref Published psilocybin DepressionAnxietyNeuroplasticityBrain ImagingMechanism of ActionReceptor PharmacologyAgingClinical TrialMeta-AnalysisReview ArticleAnimal StudyCancer PatientsTreatment-Resistant Depression Meta-Analysis

Live source coverage

3,975 indexed records across 8 active sources.

3,210Published
478Preprints
287Clinical trials
  1. Europe PMC 2,554 records · 64.3%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 283 records · 7.1%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 157 records · 3.9%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.